The Top 60: S&R Communications Group

Asked about their top priorities for the remainder of 2008 and beyond, most agency prexies don't wait for the question to end before they start spewing the words “interactive” and “digital.” But when the same question is put to Paul Dreyer, president and COO of S&R Communications Group, his answer has a decidedly more old-school bent.

S&R remains committed to targeting primary care physicians first and foremost. “With all the changes in healthcare, obviously physicians aren't the key decision-makers anymore,” he says. “We get that. But if you get the communications and message right with physicians, that's the most important first step.”
Which isn't to say that S&R has let the interactive/ digital bandwagon pass it by. The company grew its capabilities during the last year by hiring new staffers and striving to educate existing ones.

Dreyer, like just about everybody else, bemoans the pressure that the industry has faced in recent months. Still, S&R has weathered the storm, remaining about the same size (50 staffers across S&R and spun-off CME-focused sister firm Scienta Healthcare Education) despite the loss of a key client, Sepracor.

S&R had worked with Sepracor for around seven years and Dreyer admits that the loss “put a lot of pressure on us, because we had to fill the revenue loss.” That said, the firm hasn't resorted to layoffs, thanks to big successes on the new-business front. Wins included Inspire Pharmaceuticals (for the AzaSite launch) and Prestwick Pharmaceuticals (for the Xenazine launch). Siemens Medical and Mattson Jack Group tapped S&R for a range of corporate work and communications, while Sciele Pharma hired the firm to tout Zovirax.

As for the future, Dreyer expects another challenging year for the business as a whole.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.